Portal de Periódicos da CAPES

Nonalcoholic fatty liver disease: An agenda for clinical research

2002; Lippincott Williams & Wilkins; Volume: 35; Issue: 4 Linguagem: Inglês

10.1053/jhep.2002.32483

1527-3350

Zobair M. Younossi, Anna Mae Diehl, Janus P. Ong,

Liver Disease and Transplantation

HepatologyVolume 35, Issue 4 p. 746-752 Perspectives In Clinical HepatologyFree Access Nonalcoholic fatty liver disease: An agenda for clinical research Zobair M. Younossi, Corresponding Author Zobair M. Younossi [email protected] Center for Liver Diseases, Inova Fairfax Hospital, Falls Church, VACenter for Liver Diseases, Inova Fairfax Hospital, 3300 Gallows Rd., Falls Church, VA 22042. fax: 703-698-3481.===Search for more papers by this authorAnna Mae Diehl, Anna Mae Diehl Division of Gastroenterology, Johns Hopkins University, Baltimore, MDSearch for more papers by this authorJanus P. Ong, Janus P. Ong Center for Liver Diseases, Inova Fairfax Hospital, Falls Church, VASearch for more papers by this author Zobair M. Younossi, Corresponding Author Zobair M. Younossi [email protected] Center for Liver Diseases, Inova Fairfax Hospital, Falls Church, VACenter for Liver Diseases, Inova Fairfax Hospital, 3300 Gallows Rd., Falls Church, VA 22042. fax: 703-698-3481.===Search for more papers by this authorAnna Mae Diehl, Anna Mae Diehl Division of Gastroenterology, Johns Hopkins University, Baltimore, MDSearch for more papers by this authorJanus P. Ong, Janus P. Ong Center for Liver Diseases, Inova Fairfax Hospital, Falls Church, VASearch for more papers by this author First published: 30 December 2003 https://doi.org/10.1053/jhep.2002.32483Citations: 183AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 Ludwig J, Viggiano TR, McGill DB, Ott BJ. Non-alcoholic steatohepatitis. Mayo Clinic experiences with a hither to unnamed disease. Mayo Clinic Proc 1980; 55: 434–438. 2 Diehl A, Goodman Z, Ishak K. Alcohol-like liver disease in non-alcoholics. A clinical and histologic comparison with alcohol-induced liver injury. Gastroenterology 1988; 95: 1056–1062. MEDLINE 3 Falck-Ytter Y, Younossi ZM, Marchesini G, McCullough AJ. Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis 2001; 21: 17–26. MEDLINE 4 Younossi ZM. Non-alcoholic fatty liver disease. Curr Gastroenterol Reports 1999; 1: 57–61. 5 Lee RG. Non-alcoholic steatohepatitis: a study of 49 patients. Hum Pathol 1989; 20: 594–598. MEDLINE 6 Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413–1419. MEDLINE 7 Younossi ZM, Gramlich T, Liu YC, Matteoni C, Petrelli M, Goldblum J, Rybicki L, et al. Nonalcoholic fatty liver disease: assessment of variability in pathologic interpretations. Mod Path 1998; 11: 560–565. 8 Brunt EM, Janney CG, DiBisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 2467–2474. MEDLINE 9 Brunt EM. Nonalcoholic steatohepatitis: Definition and pathology. Semin Liver Dis 2001; 21: 3–16. MEDLINE 10 El-Hassan AY, Ibrahim EM, Al-Mulhim FA, Nabhan AA, Chammas MY. Fatty infiltration of the liver: analysis of prevalence, radiological and clinical features and influence on patient management. Br J Radiology 1992; 65: 774–778. 11 Bellentani S, Saccoccio G, Masutti F, Croce LS, Brandi G, Sasso F, Cristanini G, et al. Prevalence of and risk factors for hepatic steatosis in northern Italy. Ann Intern Med 2000; 132: 112–117. MEDLINE 12 Ground KEU. Liver pathology in aircrew. Aviat Space Environ Med 1982; 53: 14–18. MEDLINE 13 Hulcrantz R, Glaumann H, Lindberg G, Nilsen LH. Liver investigation in 149 asymptomatic patients with moderately elevated activities of serum aminotransferases. Scand J Gastroenterol 1986; 21: 109–113. MEDLINE 14 Jick SS, Stender M, Myers MW. Frequency of liver disease in type 2 diabetic patients treated with oral antidiabetic agents. Diabetes Care 1999; 2: 1067–2071. 15 Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001; 121: 91–100. MEDLINE 16 Kemmer NM, McKinney KH, Xiao SY, Singh H, Murray R, Abdo B, Eledrisi M, et al. High prevalence of NASH among Mexican American females with type II diabetes mellitus [Abstract]. Gastroenterology 2001; 120: A117. 17 Powell EE, Cookesley WGE, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 1990; 11: 74–80. MEDLINE 18 Teli MR, James OFW, Burt AD, Bennet MK, Day CP. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology 1995; 6: 1714–1719. 19 Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994; 107: 1103–1109. MEDLINE 20 Caldwell S, Oelsner D, Iezzoni J, Hespenheide E, Battle E, Driscoll C. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999; 29: 664–669. MEDLINE 21 Poonawala A, Nair S, Thuluvath P. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis. Hepatology 2000; 32: 689–691. MEDLINE 22 Ong J, Younossi ZM, Reddy V, Price LL, Gramlich T, Mayes J, Boparai N. Cryptogenic cirrhosis and posttransplant nonalcoholic fatty liver disease. Liver Transpl 2001; 7: 797–801. MEDLINE 23 Fong DG, Nehra V, Lindor K, Buchman AL. Metabolic and nutritional considerations in nonalcoholic fatty liver. Hepatology 2000; 32: 3–10. MEDLINE 24 Araujo LMB, DeOliveira A, Nunes DS. Liver and biliary ultrasonography in diabetic and non-diabetic obese women. Diabetes Metab 1998; 24: 458–462. MEDLINE 25 Marceau P, Biron S, Hould F, Marceau S, Simard S, Thung SN, Kral JG. Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab 1999; 84: 1513–1517. MEDLINE 26 Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, McCullough AJ, Forlani G, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999; 107: 450–455. MEDLINE 27 Angulo P, Keach JC, Butts KP, Lindor KD. Independent predictors of liver fibrosis in patients with non-alcoholic steatohepatitis. Hepatology 1999; 30: 1356–1362. MEDLINE 28 Younossi ZM, CA Matteoni CA, Gramlich T, Lin Y, Boparai N, Whol D, McCullough AJ. Patient characteristics predicting cirrhosis in non-alcoholic steatohepatitis and death in non-alcoholic steatohepatitis [Abstract]. Gastroenterology 1998; 115: 1352. 29 Chitturi S, Farrell GC. Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis 2001; 21: 27–41. MEDLINE 30 Day CP, James OFW. Steatohepatitis: a tale of two "hits"? Gastroenterology 1998; 114: 842–845. MEDLINE 31 Rao MS, Reddy JK. Peroxisomal β-oxidation and steatohepatitis. Sem Liver Dis 2001; 21: 43–55. 32 Pessayre D, Berson A, Fromenty B, Mansouri A. Mitochondria in steatohepatitis. Sem Liver Dis 2001; 21: 57–69. 33 Angulo P, Lindor KD. Treatment of nonalcoholic fatty liver: present and emerging therapies. Sem Liver Dis 2001; 21: 81–88. 34 Sheth SG, Gordon FD, Chopra S. Non-alcoholic steatohepatitis. Ann Intern Med 1997; 126: 137–145. MEDLINE 35 Eriksson S, Eriksson KF, Bondesson L. Nonalcoholic steatohepatitis in obesity: a reversible condition. Acta Med Scand 1986; 220: 83–88. MEDLINE 36 Ueno T, Sugawara H, Sujaku K, Hashimoto O, Tsuji R, Tamaki S, Turimura T, et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 1997; 27: 103–107. MEDLINE 37 Palmer M, Schaffner F. Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology 1990; 99: 1408–1413. MEDLINE 38 Franzese A, Vajro P, Argenziano A, Puzziello A, Iannucci MP, Saviano MC, Brunetti F, et al. Liver involvement in obese children: ultrasonography and liver enxyme levels at diagnosis and during follow up in an Italian population. Dig Dis Sci 1997; 42: 1428–1432. MEDLINE 39 Andersen T, Gluud C, Franzmann MB, Christoffersen P. Hepatic effects of dietary weight loss in morbidly obese subjects. J Hepatol 1991; 12: 224–229. MEDLINE 40 Drenick E, Simmons F, Murphy J. Effect on hepatic morphology of treatment of obesity by fasting, reducing diets and small bowel bypass. N Engl J Med 1970; 282: 829–834. MEDLINE 41 Basaranoglu M, Acbay O, Sonsuz A. A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis. J Hepatol 1999; 31: 384. MEDLINE 42 Horlander J, Kwo P. Atorvastatin for the treatment of NASH [Abstract]. Hepatology 1997; 26: 544A. 43 Laurin J, Lindor K, Crippin J, Gossard A, Gores GJ, Ludwig J, Ramella J, et al. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology 1996; 23: 1464–1467. MEDLINE 44 Lin HZ, Yang SQ, Chuckaree C, Kuhajda F, Ronnet G, Diehl AM. Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med 2000; 6: 998–1003. MEDLINE 45 Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M, Mechionda N. Metformin in nonalcoholic steatohepatitis. Lancet 2001; 358: 893–894. MEDLINE 46 Arioglu E, Duncan-Morin J, Sebring N, Rother KI, Gottlieb N, Lieberman J, Herion D, et al. Efficacy of safety of troglitazone in the treatment of lipodystrophy syndromes. Ann Intern Med 2000; 133: 263–274. MEDLINE 47 Caldwell SH, Hespenheide EE, Redick J, Iezzoni J, Battle EH, Sheppard BS. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol 2001; 96: 519–525. MEDLINE 48 Meydani M. Vitamin E. Lancet 1995; 345: 170–175. MEDLINE 49 Bieri J, Corash L, Hubbard V. Medical uses of vitamin E. N Engl J Med 1983; 308: 1063–1071. MEDLINE 50 Lavine JE. Vitamin E treatment on nonalcoholic steatohepatitis in children: a pilot study. J Pediatr 2000; 136: 734–738. MEDLINE 51 Abdelmalek M, Angulo P, Jorgensen R, Sylvestre P, Lindor K. Betaine for the treatment of nonalcoholic steatohepatitis: a promising new agent [Abstract]. Hepatology 2000; 32: A973. 52 Gulbahar O, Karasu Z, Ersoz G, Akarca U, A. M. Treatment of non-alcoholic steatohepatitis with N-acetylcysteine. Gastroenterology 2000; 118: A1444. 53 Abdelmalek M, Ludwig J, Lindor KD. Two cases from the spectrum of non-alcoholic steatohepatitis. J Clin Gastroenterol 1995; 20: 127–130. MEDLINE 54 Ceriani R, Brunanti S, Morini L, Sacchi E, Colombo G. Effect of ursodeoxycholic acid plus diet in patients with non-alcoholic steatohepatitis [Abstract]. Hepatology 1998; 26: 386A. 55 Guma C, Viola L, Thome M, Galdame O, Alvarez E. Ursodeoxycholic acid in the treatment of non-alcoholic steatohepatitis: results of a prospective clinical controlled trial [Abstract]. Hepatology 1997; 26: 387A. 56 Vajro P, Franzese JA, Valerio G, Iannucci MP, Aragion N. Lack of efficacy of urodeoxycholic acid for the treatment of liver abnormalities in obese children. J Pediatr 2000; 136: 739–743. MEDLINE Citing Literature Volume35, Issue4April 2002Pages 746-752 ReferencesRelatedInformation